Life Without Plavix: Sanofi Highlights Next Generation Drugs
Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.
You may also be interested in...
CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.
Sponsor of the leading GLP-1 agonist, Victoza, sees the launch of the long-acting competitor from Amylin as having a class-wide impact, drawing more patients to GLP-1s – and it thinks that it can stave off the once-weekly contender.
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices